ABT - Abbott Laboratories
SNP 500


Strong Growth and ImprovingStock Price Attractive


based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 31.31%
Operating Income Growth is 96.55%
Net Income Growth is 114.01%
Earnings Per Share (EPS) Growth is 113.23%
Net Margin is 17.05%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.83
Debt Ratio is 0.17
Current Debt to Net Income Ratio is 0.36
Total Debt to Total Assets Ratio is 0.25
Cash Flow is STRONG
Cash from Operations Growth is 72.79%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Abbott Laboratories (ABT) -
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Robert Ford
Employees - 107,000

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.